Key Highlights

● Revenue rose, led by instruments and service

● Consumables eased after the SPRQ-Nx price reset

● Top of the annual Revenue range was trimmed

● CEO named interim finance chief

Pacific Biosciences of California, Inc. (NASDAQ:PACB), the long-read genome sequencing company known as PacBio and one of the more closely followed low-priced penny stocks in life science tools, reported third-quarter results, in which total revenue edged above the prior-year period while the part of the Business built on repeat purchases moved slightly the other way. The company, which trades on the Nasdaq at a single-digit dollar share price, also said it now expects full-year revenue in a range whose upper boundary sits below the one it gave a quarter earlier.

The release, furnished to the Securities and Exchange Commission as an exhibit to a current report, showed a gain driven by instruments and by service and other revenue. Consumables, the reagents and related supplies that customers purchase each time they run the machines, came in a little below the year-ago figure. For a sequencing company, that mix is worth attention, because installed systems are typically expected to generate a steady stream of follow-on consumable purchases over their working lives.

The explanation sits largely in a decision PacBio made earlier in the year. In May, according to market data, the company launched SPRQ-Nx chemistry, multi-use SMRT cells and a software update for its Revio system, sharply lowering the US list price of a whole human genome. A lower price per genome reduces the revenue collected per unit of sequencing until Volume responds. The third quarter offers an early look at where that exchange stands.

How the Revenue Lines Moved

Instrument revenue rose from the prior-year quarter as the company placed modestly more Revio systems and modestly more of its benchtop Vega systems. PacBio said its Vega deliveries were dominated by new customers, with the great majority of units going to buyers that had not previously owned the platform. That detail points to a widening of the customer base, although Vega is the benchtop member of the product family.

Service and other revenue also increased. Consumable revenue, by contrast, slipped from the prior-year quarter. The annualized pull-through per Revio system, a measure of how much consumable revenue each installed machine generates, fell noticeably from the year-ago level. This is the metric most directly exposed to the price reset, since each SPRQ-Nx customer now pays less for a comparable genome.

Over the year to date, total revenue was only slightly above the same period of last year. The quarter therefore represented a modest improvement in a year that has otherwise been close to flat. According to market data, second-quarter revenue had fallen short of analyst estimates and had declined from the prior-year quarter, so the latest gain marks a change of direction from the previous report, if a small one.

The SPRQ-Nx Bargain

The company said more than half of Revio consumables revenue is now tied to SPRQ-Nx, and that a clear majority of the Revio installed base had opted to upgrade its software to use the chemistry by the end of the quarter. Market data had reported that at the time of the prior quarter, only a minority of the installed base had upgraded, with the company then projecting a move past the halfway mark by the end of the third quarter. On the evidence of the release, that adoption goal was exceeded.

Chief Executive Mark Van Oene framed the shift in direct terms, saying that "SPRQ-Nx is changing the Economics of HiFi sequencing." The chemistry works in part by allowing a single SMRT cell to be reused. Market commentary noted management as saying that HiFi Yield was nearly identical across the initial uses of a cell and declined slightly on the last permitted run.

SPRQ-Nx for Vega launched in late August, extending the same approach to the benchtop instrument. The Vega update was designed to raise output per run while lowering the US list price per run, reducing cost per unit of data. The release describes the launch but does not quantify any resulting demand, and the Vega version has been on the market for only part of the quarter under review.

The commercial argument for a price cut of this kind is that lower cost per genome opens up projects that were previously unaffordable, particularly large cohort studies and routine clinical use. The third-quarter data do not settle whether that elasticity will arrive in sufficient size. They do show that customers adopted the cheaper chemistry quickly, and that consumable revenue had not yet returned to its earlier level as they did so.

Margin Pressure From Memory Chips and a Factory Move

Gross Margin narrowed from the prior-year quarter on both a GAAP and a non-GAAP basis, with Gross Profit falling even as revenue rose. Management attributed the non-GAAP decline mainly to higher memory costs and to expenses tied to the Vega Manufacturing transition. Market data had reported in the prior quarter that the company was absorbing temporary Vega manufacturing transition costs along with rising compute and memory costs, so neither Factor is new.

These pressures differ in character. A manufacturing transition is, by its nature, a passing cost, and the company had described it as temporary. Memory pricing depends on a market outside the control of an instrument maker, and the release gives no forecast for it. The contrast matters for anyone trying to separate one-off margin effects from those that could persist into next year.

Cost Reductions Show Up in Operating Expenses

Operating expenses fell on both a GAAP and non-GAAP basis from the year-ago quarter, which the company attributed to lower personnel costs following restructuring. PacBio had confirmed layoffs at the time of its second-quarter report. Research and Development spending and sales, general and administrative costs both declined, and share-based compensation was also lower.

As a result, the net loss on a GAAP basis was almost unchanged from the prior-year quarter despite the weaker gross profit, while the non-GAAP net loss narrowed. Net loss per share improved slightly, helped in part by a larger weighted share count. Even so, the operating loss remained large relative to revenue, as total Operating Expense continued to exceed revenue by a wide margin.

The year-to-date comparison requires care. GAAP net loss for the period was far smaller than a year earlier, but last year included large Impairment and amortization charges, and this year included a gain on the disposal of short-read Assets alongside litigation settlement charges connected to Personal Genomics of Taiwan. The non-GAAP figures, which strip out such items, show a much more modest improvement, and they provide the clearer view of the underlying trend.

Cash, Convertible Notes and a Shrinking Cushion

Cash, cash equivalents and investments declined during the quarter and stood well below both the year-end level and the figure from a year earlier. The balance is the central number in the company's financial position, because operations continue to consume cash while a large amount of convertible senior notes remains on the balance sheet. The carrying value of those notes is several times the size of the cash and investments line.

Stockholders' Equity moved into a Deficit at the end of September, compared with a small positive figure at the end of last year. Inventory rose during the same period while Accounts Payable fell. Total assets also declined, and Goodwill continued to account for a substantial share of what remains.

The release does not present any new financing, and it does not state a repayment plan for the notes. Those absences do not imply any imminent event, but they leave the company's path dependent on cost control and on revenue growth from a lower price base.

A Finance Chief Departs and the Chief Executive Steps In

The same filing carried a management change. A current report showed that Chief Financial Officer Jim Gibson stepped down at the start of recently and moved into a non-executive advisory role to the chief executive, with employment continuing through a transition period that runs to the end of March next year. The expected transition terms, including a conditional severance payment, remained subject to the signing of a transition agreement.

Van Oene, who remains president and chief executive, was appointed interim chief financial officer and principal financial officer until a successor is named, with no change in his compensation. The board plans to search for a permanent finance chief. Bill Meyer, who became corporate controller in August after a period as vice president of finance at Visby Medical, was appointed chief accounting officer and principal accounting officer.

The change follows a broader Leadership turnover. Market commentary noted in connection with the second-quarter results that Christian Henry had left the chief executive role with immediate effect, that Van Oene had replaced him, and that no reason was given. Henry stayed on the board and took an advisory role. In a matter of months, then, the company has changed both its chief executive and its finance chief, and it now has one person filling both posts on an interim basis for the finance role.

Clinical Customers Move Toward the Centre

PacBio used the release to emphasize clinical adoption, and external material supports the direction of travel. Clinical consumables shipments grew strongly in the second quarter and made up a meaningful minority of total consumables shipments. The third-quarter release adds a Partnership aimed at bringing long-read whole genome sequencing into the testing portfolio of GeneDx, with a focus on rare disease and clinical work.

GeneDx's own announcement in October said it plans to add long-read whole genome sequencing to its genome testing portfolio and to offer the test upfront to eligible patients, with an early access program to be available by the end of the year. The GeneDx statement refers to collaborations with technology partners without naming PacBio, while the PacBio release identifies the relationship from its side.

The clinical case rests on what long reads can detect. GeneDx said the approach helps identify complex variation, including certain structural variants and repeat expansions that short-read sequencing can miss, and that a targeted strategy aims to reduce sequential testing and speed up diagnosis. A PacBio post recapping the American Society of Human Genetics meeting, published a day after the results, cited presentations from customers including Children's Mercy Kansas City, which reported a shorter mean turnaround than with standard testing. That post is company material, though it attributes the results to the institutions presenting them.

PacBio notes that its products are for research use only. The disclaimer accompanies its partnership announcements as well, including the Verily Health release.

Biomedical AI as a New Source of Demand

A second theme in the update concerned the use of sequencing data to train AI models. In October, PacBio and Verily Health announced a multi-year collaboration combining HiFi sequencing with Verily's data and AI platform, linking sequencing workflows to Verily Pre and pairing long-read genomic data with real-world clinical data. The partners said they aim to produce AI-ready clinico-genomic datasets. Verily's Workbench, according to the announcement, serves a large community of researchers.

Separately, the release described a collaboration with TychoBio to generate full-length RNA datasets using HiFi and Kinnex sequencing, intended to train AI models on the efficacy and off-target effects of RNA therapies. PacBio's conference post said such customers value accurate sequence, native methylation and full-length transcripts because they Supply consistent, multi-layered inputs for model training.

They are better read as indications of where the company sees new Demand than as evidence of its current size.

Population Programs and the Global Picture

Large research programs remain relevant. The release cited a multi-year Department of Veterans Affairs contract awarded to customer Sampled for long-read whole genome analyses in a major veterans genomics program. It also pointed to the participation of Berry Genomics in the Birth Defects Project, a large genomics study in China, which places HiFi sequencing at the centre of research in the Asia-Pacific region.

That region had been a soft spot. Second-quarter Asia-Pacific revenue fell sharply because a large population sequencing program ended, because of funding pressure, and because customers were using up reagent inventory during SPRQ-Nx validation. In the Americas, management had blamed weaker Vega sales on funding uncertainty among US academic and government customers, including the National Institutes of Health, and said it assumed no recovery in those funds. Europe, the Middle East and Africa had been the bright spot in that report, helped by clinical adoption and a national genomics deal.

An Outlook Narrowed From the Top

PacBio now expects full-year revenue in a range with the same lower boundary as the previous outlook but a reduced upper boundary, according to the comparison between the release and the prior guidance reported by market data. That prior range had itself been a reduction from an earlier one. Set against year-to-date revenue, the new range implies fourth-quarter revenue around the level just reported, while market data had reported management expecting growth to accelerate in the second half.

The items likely to define the coming quarters are visible in the company's own disclosures: whether consumable revenue recovers as SPRQ-Nx volume builds, whether Vega transition costs fade as planned, how quickly the cash balance continues to decline, and who is appointed as permanent finance chief. The GeneDx early access program, due by year-end, adds a further external marker for clinical demand. These are reporting items rather than forecasts, and the release offers no assurance on any of them.